Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) announced on Oct 3, 2025 that on Sept 19, 2025 its Compensation Committee granted inducement awards to eight newly hired employees under the 2023 Inducement Plan.

The grants consist of 76,360 stock options (10‑year term) and 16,361 RSUs. The option exercise price is $30.40 per share (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months); RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to plan and award agreement terms and continued employment.

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 76,360 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 16,361 shares of Vor Bio’s common stock to eight newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and the exercise price is $30.40 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

FAQ

What did Vor Bio (VOR) announce on Oct 3, 2025 about inducement grants?

Vor Bio disclosed Sept 19, 2025 inducement awards: 76,360 stock options and 16,361 RSUs to eight new hires under the 2023 Inducement Plan.

What is the exercise price and term for VOR stock options granted Sept 19, 2025?

Options have a 10‑year term with an exercise price of $30.40 per share, equal to the closing price on the grant date.

How do the VOR options and RSUs vest for the new hires?

Both awards vest over four years: 25% after 12 months; options vest monthly thereafter, RSUs vest quarterly thereafter, subject to continued employment.

Will the VOR inducement grants dilute existing shareholders immediately?

The press release lists grant sizes but does not state total outstanding shares or expected dilution percentage.

Under which plan were Vor Bio's Oct 2025 inducement awards granted?

Awards were granted under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Vor Bio (VOR) on Sept 19, 2025?

Eight newly hired employees received the stock options and RSU inducement awards.